Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enzo Biochem, a developer of healthcare products and technologies, has announced that its Enzo Clinical Labs subsidiary has appointed Kevin Krenitsky as its new president.
Subscribe to our email newsletter
Prior to joining Enzo Clinical Labs, Dr Krenitsky, who is replacing Shahram Rabbani, was CEO of Bioserve Biotechnologies. Prior to Bioserve, he was CEO of Parkway Clinical Laboratories.
Dr Krenitsky previously served as senior vice president and division head at SeraCare Life Sciences’s genomics collaborative division, where he managed all worldwide diagnostic and pharmaceutical R&D collaborations. Dr Krenitsky has received his MD from Jefferson Medical College.
Barry Weiner, president of Enzo Biochem, said: “Kevin’s impressive credentials in the clinical service, molecular diagnostics, and preclinical and clinical pharma, should serve us well as we continue to develop Enzo Clinical Labs into a molecular and esoteric center of excellence. Kevin’s extensive operational experience along with his success in the launching of new service offerings will be instrumental in growing Enzo Clinical Labs.”